Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 68
Filter
1.
Int J Mol Sci ; 22(17)2021 Sep 06.
Article in English | MEDLINE | ID: mdl-34502556

ABSTRACT

c-Jun N-terminal kinases (JNKs) are among the most crucial mitogen-activated protein kinases (MAPKs) and regulate various cellular processes, including cell proliferation, apoptosis, autophagy, and inflammation. Microbes heavily rely on cellular signaling pathways for their effective replication; hence, JNKs may play important roles in infectious diseases. In this review, we describe the basic signaling properties of MAPKs and JNKs in apoptosis, autophagy, and inflammasome activation. Furthermore, we discuss the roles of JNKs in various infectious diseases induced by viruses, bacteria, fungi, and parasites, as well as their potential to serve as targets for the development of therapeutic agents for infectious diseases. We expect this review to expand our understanding of the JNK signaling pathway's role in infectious diseases and provide important clues for the prevention and treatment of infectious diseases.


Subject(s)
Communicable Diseases/enzymology , MAP Kinase Signaling System , Mitogen-Activated Protein Kinase 10/metabolism , Mitogen-Activated Protein Kinase 8/metabolism , Mitogen-Activated Protein Kinase 9/metabolism , Animals , Apoptosis , Autophagy , Communicable Diseases/metabolism , Communicable Diseases/pathology , Humans , Phosphorylation
2.
Sci Rep ; 11(1): 800, 2021 01 12.
Article in English | MEDLINE | ID: mdl-33436713

ABSTRACT

Risk factors associated with 72-h mortality in patients with extremely high serum aspartate aminotransferase levels (AST; ≥ 3000 U/L) are unknown. This single-centre, retrospective, case-controlled, cross-sectional study obtained data from medical records of adult patients treated at Saitama Medical Center, Japan, from 2005 to 2019. We conducted a multivariate logistic after adjusting for age, sex, height, weight, body mass index, Brinkman Index, vital signs, biochemical values, updated Charlson Comorbidity Index (CCI) score, CCI components, and underlying causes. A logistic regression model with selected validity risks and higher C-statistic for predicting 72-h mortality was established. During the 15-year period, 428 patients (133 non-survivors and 295 survivors [cases and controls by survival < 72 and ≥ 72 h, respectively]) with AST levels ≥ 3000 U/L were identified. The 72-h mortality rate was 133/428 (31.1%). The model used for predicting 72-h mortality through the assessment of alkaline phosphatase, creatine kinase, serum sodium, potassium, and phosphorus levels had a C-statistic value of 0.852 (sensitivity and specificity, 76.6%). The main independent risk factors associated with 72-h mortality among patients with AST levels ≥ 3000 U/L included higher serum values of alkaline phosphatase, creatine kinase, serum sodium, potassium, and phosphorus.


Subject(s)
Alanine Transaminase/blood , Aspartate Aminotransferases/blood , Communicable Diseases/mortality , Creatine Kinase/blood , Adult , Aged , Aged, 80 and over , Biomarkers/blood , Case-Control Studies , Clinical Laboratory Techniques/methods , Clinical Laboratory Techniques/statistics & numerical data , Communicable Diseases/blood , Communicable Diseases/enzymology , Cross-Sectional Studies , Female , Humans , Japan/epidemiology , Male , Middle Aged , ROC Curve , Retrospective Studies , Risk Factors , Survival Rate , Young Adult
3.
Int J Mol Sci ; 21(18)2020 Sep 17.
Article in English | MEDLINE | ID: mdl-32957626

ABSTRACT

Eukaryotic proteomes are enormously sophisticated through versatile post-translational modifications (PTMs) of proteins. A large variety of code generated via PTMs of proteins by ubiquitin (ubiquitination) and ubiquitin-like proteins (Ubls), such as interferon (IFN)-stimulated gene 15 (ISG15), small ubiquitin-related modifier (SUMO) and neural precursor cell expressed, developmentally downregulated 8 (NEDD8), not only provides distinct signals but also orchestrates a plethora of biological processes, thereby underscoring the necessity for sophisticated and fine-tuned mechanisms of code regulation. Deubiquitinases (DUBs) play a pivotal role in the disassembly of the complex code and removal of the signal. Ubiquitin-specific protease 18 (USP18), originally referred to as UBP43, is a major DUB that reverses the PTM of target proteins by ISG15 (ISGylation). Intriguingly, USP18 is a multifaceted protein that not only removes ISG15 or ubiquitin from conjugated proteins in a deconjugating activity-dependent manner but also acts as a negative modulator of type I IFN signaling, irrespective of its catalytic activity. The function of USP18 has become gradually clear, but not yet been completely addressed. In this review, we summarize recent advances in our understanding of the multifaceted roles of USP18. We also highlight new insights into how USP18 is implicated not only in physiology but also in pathogenesis of various human diseases, involving infectious diseases, neurological disorders, and cancers. Eventually, we integrate a discussion of the potential of therapeutic interventions for targeting USP18 for disease treatment.


Subject(s)
Autoimmune Diseases/metabolism , Communicable Diseases/metabolism , Cytokines/metabolism , Deubiquitinating Enzymes/metabolism , Interferons/metabolism , Neoplasms/metabolism , Nervous System Diseases/metabolism , Ubiquitin Thiolesterase/metabolism , Amino Acid Sequence , Animals , Autoimmune Diseases/enzymology , Communicable Diseases/enzymology , Communicable Diseases/microbiology , Communicable Diseases/virology , Cytokines/genetics , Humans , Neoplasms/enzymology , Nervous System Diseases/enzymology , Protein Processing, Post-Translational , Signal Transduction/genetics , Ubiquitin Thiolesterase/chemistry , Ubiquitin Thiolesterase/genetics , Ubiquitination/genetics , Ubiquitins/genetics , Ubiquitins/metabolism
4.
ACS Chem Biol ; 15(7): 1747-1758, 2020 07 17.
Article in English | MEDLINE | ID: mdl-32453941

ABSTRACT

Protein myristoylation, the addition of a 14-carbon saturated acyl group, is an abundant modification implicated in biological events as diverse as development, immunity, oncogenesis, and infections. N-Myristoyltransferase (NMT) is the enzyme that catalyzes this modification. Many elegant studies have established the rules guiding the catalysis including substrate amino acid sequence requirements with the indispensable N-terminal glycine, and a co-translational mode of action. Recent advances in technology such as the development of fatty acid analogs, small molecule inhibitors, and new proteomic strategies, allowed a deeper insight into the NMT activity and function. Here we focus on discussing recent work demonstrating that NMT is also a lysine myristoyltransferase, the enzyme's regulation by a previously unnoticed solvent channel, and the mechanism of NMT regulation by protein-protein interactions. We also summarize recent findings on NMT's role in cancer, immunity, and infections and the advances in pharmacological targeting of myristoylation. Our analyses highlight opportunities for further understanding and discoveries.


Subject(s)
Acyltransferases/metabolism , Communicable Diseases/physiopathology , Immunity, Innate/physiology , Neoplasms/metabolism , Proteins/metabolism , Acyltransferases/antagonists & inhibitors , Animals , Communicable Diseases/drug therapy , Communicable Diseases/enzymology , Enzyme Inhibitors/therapeutic use , Glycine/chemistry , Glycine/metabolism , Humans , Lysine/chemistry , Lysine/metabolism , Neoplasms/enzymology , Protein Processing, Post-Translational
5.
Biosensors (Basel) ; 11(1)2020 Dec 31.
Article in English | MEDLINE | ID: mdl-33396519

ABSTRACT

The United States Centers for Disease Control and Prevention considers saliva contact the lead transmission means of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which causes the coronavirus disease 2019 (COVID-19). Saliva droplets or aerosols expelled by heavy breathing, talking, sneezing, and coughing may carry this virus. People in close distance may be exposed directly or indirectly to these droplets, especially those droplets that fall on surrounding surfaces and people may end up contracting COVID-19 after touching the mucosa tissue on their faces. It is of great interest to quickly and effectively detect the presence of SARS-CoV-2 in an environment, but the existing methods only work in laboratory settings, to the best of our knowledge. However, it may be possible to detect the presence of saliva in the environment and proceed with prevention measures. However, detecting saliva itself has not been documented in the literature. On the other hand, many sensors that detect different organic components in saliva to monitor a person's health and diagnose different diseases that range from diabetes to dental health have been proposed and they may be used to detect the presence of saliva. This paper surveys sensors that detect organic and inorganic components of human saliva. Humidity sensors are also considered in the detection of saliva because a large portion of saliva is water. Moreover, sensors that detect infectious viruses are also included as they may also be embedded into saliva sensors for a confirmation of the virus' presence. A classification of sensors by their working principle and the substance they detect is presented. This comparison lists their specifications, sample size, and sensitivity. Indications of which sensors are portable and suitable for field application are presented. This paper also discusses future research and challenges that must be resolved to realize practical saliva sensors. Such sensors may help minimize the spread of not only COVID-19 but also other infectious diseases.


Subject(s)
Biological Monitoring/instrumentation , COVID-19/prevention & control , SARS-CoV-2/isolation & purification , Saliva/chemistry , Saliva/virology , Biological Monitoring/methods , COVID-19/enzymology , COVID-19/etiology , COVID-19/immunology , Communicable Diseases/enzymology , Communicable Diseases/etiology , Communicable Diseases/immunology , Communicable Diseases/virology , Humans , Influenza A Virus, H1N1 Subtype/chemistry , Influenza A Virus, H1N1 Subtype/enzymology , Influenza A Virus, H1N1 Subtype/immunology , Influenza A Virus, H1N1 Subtype/isolation & purification , SARS-CoV-2/chemistry , SARS-CoV-2/immunology , Saliva/enzymology , Saliva/immunology , Viruses/chemistry , Viruses/enzymology , Viruses/immunology , Viruses/isolation & purification
6.
Immunology ; 159(2): 142-155, 2020 02.
Article in English | MEDLINE | ID: mdl-31630388

ABSTRACT

Inflammation is a part of the body's immune response for protection against pathogenic infections and other cellular damages; however, chronic inflammation is a major cause of various diseases. One key step in the inflammatory response is the activation of inflammasomes, intracellular protein complexes comprising pattern recognition receptors and other inflammatory molecules. The role of the NLRP3 inflammasome in inflammatory responses has been extensively investigated; however, the caspase-11 inflammasome has been recently identified and has been classified as a 'non-canonical' inflammasome, and emerging studies have highlighted its role in inflammatory responses. Because the ligands and the mechanisms for the activation of these two inflammasomes are different, studies to date have separately described their roles, although recent studies have reported the functional cooperation between these two inflammasomes during an inflammatory response. This review discusses the studies investigating the functional crosstalk between non-canonical caspase-11 and canonical NLRP3 inflammasomes in the context of inflammatory responses; moreover, it provides insight for the development of novel anti-inflammatory therapeutics to prevent and treat infectious and inflammatory diseases.


Subject(s)
Caspases/metabolism , Communicable Diseases/enzymology , Inflammasomes/metabolism , Inflammation/enzymology , NLR Family, Pyrin Domain-Containing 3 Protein/metabolism , Animals , Caspases/immunology , Communicable Diseases/immunology , Host-Pathogen Interactions , Humans , Inflammasomes/immunology , Inflammation/immunology , NLR Family, Pyrin Domain-Containing 3 Protein/immunology , Signal Transduction
7.
J Proteome Res ; 18(5): 1929-1938, 2019 05 03.
Article in English | MEDLINE | ID: mdl-30913880

ABSTRACT

As cellular metabolic hubs, mitochondria are the main energy producers for the cell. These organelles host essential energy producing biochemical processes, including the TCA cycle, fatty acid oxidation, and oxidative phosphorylation. An accumulating body of literature has demonstrated that a majority of mitochondrial proteins are decorated with diverse posttranslational modifications (PTMs). Given the critical roles of these proteins in cellular metabolic pathways and response to environmental stress or pathogens, understanding the role of PTMs in regulating their functions has become an area of intense investigation. A major family of enzymes that regulate PTMs within the mitochondria are sirtuins (SIRTs). Albeit until recently the least understood sirtuin, SIRT4 has emerged as an enzyme capable of removing diverse PTMs from its substrates, thereby modulating their functions. SIRT4 was shown to have ADP-ribosyltransferase, deacetylase, lipoamidase, and deacylase enzymatic activities. As metabolic dysfunction is linked to human disease, SIRT4 levels and activities have been implicated in modulating susceptibility to hyperinsulinemia and diabetes, liver disease, cancer, neurodegeneration, heart disease, aging, and pathogenic infections. Therefore, SIRT4 has emerged as a possible candidate for targeted therapeutics. Here, we discuss the diverse enzymatic activities and substrates of SIRT4 and its roles in human health and disease.


Subject(s)
Aging/genetics , Mitochondria/enzymology , Mitochondrial Proteins/genetics , Protein Processing, Post-Translational , Sirtuins/genetics , Aging/metabolism , Communicable Diseases/drug therapy , Communicable Diseases/enzymology , Communicable Diseases/genetics , Diabetes Mellitus/drug therapy , Diabetes Mellitus/enzymology , Diabetes Mellitus/genetics , Gene Expression , Heart Diseases/drug therapy , Heart Diseases/enzymology , Heart Diseases/genetics , Humans , Hyperinsulinism/drug therapy , Hyperinsulinism/enzymology , Hyperinsulinism/genetics , Liver Diseases/drug therapy , Liver Diseases/enzymology , Liver Diseases/genetics , Mitochondria/drug effects , Mitochondria/pathology , Mitochondrial Proteins/chemistry , Mitochondrial Proteins/metabolism , Molecular Targeted Therapy/methods , Neoplasms/drug therapy , Neoplasms/enzymology , Neoplasms/genetics , Neurodegenerative Diseases/drug therapy , Neurodegenerative Diseases/enzymology , Neurodegenerative Diseases/genetics , Protein Conformation , Sirtuins/chemistry , Sirtuins/metabolism , Substrate Specificity
8.
IUBMB Life ; 70(9): 869-880, 2018 09.
Article in English | MEDLINE | ID: mdl-29761622

ABSTRACT

Infectious diseases are a major challenge in management of human health worldwide. Recent literature suggests that host immune system could be modulated to ameliorate the pathogenesis of infectious disease. Heme oxygenase (HMOX1) is a key regulator of cellular signaling and it could be modulated using pharmacological reagents. HMOX1 is a cytoprotective enzyme that degrades heme to generate carbon monoxide (CO), biliverdin, and molecular iron. CO and biliverdin (or bilirubin derived from it) can restrict the growth of a few pathogens. Both of these also induce antioxidant pathways and anti-inflammatory pathways. On the other hand, molecular iron can induce proinflammatory pathway besides making the cellular environment oxidative in nature. Since microbial infections often induce oxidative stress in host cells/tissues, role of HMOX1 has been analyzed in the pathogenesis of number of infections. In this review, we have described the role of HMOX1 in pathogenesis of bacterial infections caused by Mycobacterium species, Salmonella and in microbial sepsis. We have also provided a succinct overview of the role of HMOX1 in parasitic infections such as malaria and leishmaniasis. In the end, we have also elaborated the role of HMOX1 in viral infections such as AIDS, hepatitis, dengue, and influenza. © 2018 IUBMB Life, 70(9):869-880, 2018.


Subject(s)
Antioxidants , Communicable Diseases/enzymology , Heme Oxygenase-1/metabolism , Oxidative Stress , Animals , Communicable Diseases/etiology , Communicable Diseases/pathology , Communicable Diseases/therapy , Humans , Oxidation-Reduction
9.
PLoS One ; 13(3): e0194612, 2018.
Article in English | MEDLINE | ID: mdl-29579063

ABSTRACT

Protein myristoylation is a key protein modification carried out by N-Myristoyltransferase (NMT) after Methionine aminopeptidase 2 (MetAP2) removes methionine from the amino-terminus of the target protein. Protein myristoylation by NMT augments several signaling pathways involved in a myriad of cellular processes, including developmental pathways and pathways that when dysregulated lead to cancer or immune dysfunction. The emerging evidence pointing to NMT-mediated myristoylation as a major cellular regulator underscores the importance of understanding the framework of this type of signaling event. Various studies have investigated the role that myristoylation plays in signaling dysfunction by examining differential gene or protein expression between normal and diseased states, such as cancers or following HIV-1 infection, however no study exists that addresses the role of microRNAs (miRNAs) in the regulation of myristoylation. By performing a large scale bioinformatics and functional analysis of the miRNAs that target key genes involved in myristoylation (NMT1, NMT2, MetAP2), we have narrowed down a list of promising candidates for further analysis. Our condensed panel of miRNAs identifies 35 miRNAs linked to cancer, 21 miRNAs linked to developmental and immune signaling pathways, and 14 miRNAs linked to infectious disease (primarily HIV). The miRNAs panel that was analyzed revealed several NMT-targeting mRNAs (messenger RNA) that are implicated in diseases associated with NMT signaling alteration, providing a link between the realms of miRNA and myristoylation signaling. These findings verify miRNA as an additional facet of myristoylation signaling that must be considered to gain a full perspective. This study provides the groundwork for future studies concerning NMT-transcript-binding miRNAs, and will potentially lead to the development of new diagnostic/prognostic biomarkers and therapeutic targets for several important diseases.


Subject(s)
Acyltransferases/metabolism , Aminopeptidases/metabolism , Communicable Diseases/diagnosis , Metalloendopeptidases/metabolism , MicroRNAs/metabolism , Neoplasms/diagnosis , Acyltransferases/genetics , Aminopeptidases/genetics , B-Lymphocytes/cytology , B-Lymphocytes/metabolism , Cluster Analysis , Communicable Diseases/enzymology , Communicable Diseases/genetics , ErbB Receptors/metabolism , Humans , Metalloendopeptidases/genetics , MicroRNAs/genetics , Neoplasms/enzymology , Neoplasms/genetics , Protein Binding , Protein Processing, Post-Translational , RNA, Messenger/metabolism , Signal Transduction/genetics , T-Lymphocytes/cytology , T-Lymphocytes/metabolism
10.
J Cell Physiol ; 233(4): 2920-2927, 2018 04.
Article in English | MEDLINE | ID: mdl-28574577

ABSTRACT

Elevated plasma low-density lipoprotein-cholesterol (LDL-C) concentration is the most important risk factor for atherosclerotic cardiovascular diseases (CVDs). Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a ubiquitously expressed serine proteinase which plays a key role in cholesterol metabolism, but has been found to be implicated in some other lipid-independent physiological processes. In this review, the role of PCSK9 was evaluated not only concerning lipid metabolism but also hepatitis C virus (HCV) infection, bacterial infections/sepsis, and septic shock. Collected data from clinical trials revealed that treatment with PCSK9 inhibitors has beneficial effects in lowering LDL-C via inhibition of LDL-receptors (LDL-R), an antiviral effect on HCV infection via down-regulating the surface expression of LDL-R and CD81 on hepatic cells, and a positive association with increased inflammatory responses, as well as with septic shock by down-regulation of hepatocyte LDL-R. On the other hand, PCSK9 inhibition by therapeutic fully humanized antibodies has positive effects in reducing elevated LDL-C. However, their safety and tolerability is an important issue which has to be taken into consideration.


Subject(s)
Communicable Diseases/enzymology , Proprotein Convertase 9/metabolism , Animals , Clinical Trials as Topic , Humans , Lipid Metabolism , PCSK9 Inhibitors , Receptors, LDL/metabolism , Risk Factors
11.
PLoS One ; 12(8): e0183027, 2017.
Article in English | MEDLINE | ID: mdl-28837586

ABSTRACT

Nicotinamide phosphoribosyl transferase (NAMPT) is an inflammatory adipocytokine shown to interact in immune modulation in chronic inflammatory diseases, acute respiratory distress syndrome, sepsis, cancer and obesity in adulthood. It is, however, not clear whether this association reflects a chronic elevation or acute inflammatory response. We analyzed NAMPT concentrations in distinct states of inflammation in 102 children and found consistently significantly increased NAMPT levels in subjects with acute infections. NAMPT concentrations in children with stable chronic inflammatory diseases were not significantly different, whereas in patients with acute relapse of chronic disease NAMPT was significantly higher than in children in remission or healthy controls. In states of low-grade inflammation (children with atopic disease or obesity) we did not detect alterations in NAMPT serum levels. NAMPT correlated positively with inflammatory markers such as CRP. The most predictive factor for NAMPT serum concentrations was leucocyte count and therein the neutrophil count. Furthermore, systemic circulating NAMPT levels were closely associated with NAMPT release from corresponding cultured PBMCs. In conclusion, NAMPT is selectively increased in states of acute but not chronic inflammation in children. The close relationship between systemic circulating NAMPT with leucocyte counts and release indicate that leucocytes most probably are the source of inflammation related NAMPT levels.


Subject(s)
Communicable Diseases/enzymology , Cytokines/blood , Inflammation/enzymology , Nicotinamide Phosphoribosyltransferase/blood , Adolescent , Child , Chronic Disease , Cohort Studies , Communicable Diseases/blood , Female , Humans , Inflammation/blood , Male , Recurrence
12.
Clin Biochem ; 50(13-14): 804-811, 2017 Sep.
Article in English | MEDLINE | ID: mdl-28433610

ABSTRACT

The paraoxonases (PON1, PON2 and PON3) are an enzyme family with a high structural homology. All of them have lactonase activity and degrade lipid peroxides in lipoproteins and cells. As such, they play a role in protection against oxidation and inflammation. Infectious diseases are often associated with oxidative stress and an inflammatory response. Infection and inflammation trigger a cascade of reactions in the host, known as the acute-phase response. This response is associated with dramatic changes in serum proteins and lipoproteins, including a decrease in serum PON1 activity. These alterations have clinical consequences for the infected patient, including an increased risk for cardiovascular diseases, and an impaired protection against the formation of antibiotic-resistant bacterial biofilms. Several studies have investigated the value of serum PON1 measurement as a biomarker of the infection process. Low serum PON1 activities are associated with poor survival in patients with severe sepsis. In addition, preliminary studies suggest that serum PON1 concentration and/or enzyme activity may be useful as markers of acute concomitant infection in patients with an indwelling central venous catheter. Investigating the associations between paraoxonases and infectious diseases is a recent, and productive, line of research.


Subject(s)
Aryldialkylphosphatase/metabolism , Communicable Diseases/enzymology , Immunity, Innate , Models, Biological , Oxidative Stress , Acute-Phase Reaction/blood , Acute-Phase Reaction/enzymology , Acute-Phase Reaction/immunology , Acute-Phase Reaction/microbiology , Animals , Aryldialkylphosphatase/blood , Aryldialkylphosphatase/chemistry , Aryldialkylphosphatase/genetics , Biomarkers/blood , Catheters, Indwelling/adverse effects , Catheters, Indwelling/microbiology , Central Venous Catheters/adverse effects , Central Venous Catheters/microbiology , Communicable Diseases/blood , Communicable Diseases/immunology , Communicable Diseases/microbiology , Cross Infection/blood , Cross Infection/enzymology , Cross Infection/immunology , Cross Infection/microbiology , Humans , Polymorphism, Genetic , Promoter Regions, Genetic , Sepsis/blood , Sepsis/enzymology , Sepsis/immunology , Sepsis/microbiology , Structural Homology, Protein
13.
Biochem Pharmacol ; 133: 139-151, 2017 06 01.
Article in English | MEDLINE | ID: mdl-27865713

ABSTRACT

Natural products have served as the main source of drugs and drug leads, and natural products produced by microorganisms are one of the most prevalent sources of clinical antibiotics. Their unparalleled structural and chemical diversities provide a basis to investigate fundamental biological processes while providing access to a tremendous amount of chemical space. There is a pressing need for novel antibiotics with new mode of actions to combat the growing challenge of multidrug resistant pathogens. This review begins with the pioneering discovery and biological activities of platensimycin (PTM) and platencin (PTN), two antibacterial natural products isolated from Streptomyces platensis. The elucidation of their unique biochemical mode of action, structure-activity relationships, and pharmacokinetics is presented to highlight key aspects of their biological activities. It then presents an overview of how microbial genomics has impacted the field of PTM and PTN and revealed paradigm-shifting discoveries in terpenoid biosynthesis, fatty acid metabolism, and antibiotic and antidiabetic therapies. It concludes with a discussion covering the future perspectives of PTM and PTN in regard to natural products discovery, bacterial diterpenoid biosynthesis, and the pharmaceutical promise of PTM and PTN as antibiotics and for the treatment of metabolic disorders. PTM and PTN have inspired new discoveries in chemistry, biology, enzymology, and medicine and will undoubtedly continue to do so.


Subject(s)
Adamantane/chemistry , Adamantane/metabolism , Aminobenzoates/chemistry , Aminobenzoates/metabolism , Aminophenols/chemistry , Aminophenols/metabolism , Anilides/chemistry , Anilides/metabolism , Anti-Infective Agents/chemistry , Anti-Infective Agents/metabolism , Polycyclic Compounds/chemistry , Polycyclic Compounds/metabolism , Adamantane/therapeutic use , Aminobenzoates/therapeutic use , Aminophenols/therapeutic use , Anilides/therapeutic use , Animals , Anti-Infective Agents/therapeutic use , Communicable Diseases/drug therapy , Communicable Diseases/enzymology , Communicable Diseases/metabolism , Humans , Polycyclic Compounds/therapeutic use , Protein Structure, Secondary , Protein Structure, Tertiary , Structure-Activity Relationship
14.
Med Res Rev ; 37(3): 475-513, 2017 05.
Article in English | MEDLINE | ID: mdl-27862081

ABSTRACT

Arginase (EC 3.5.3.1) is the bimanganese enzyme that converts L-arginine into ornithine and urea. This enzyme was discovered more than a century ago and early α-amino acids were identified as weak inhibitors. It was only during the 90s, after nitric oxide (NO) was reported as one of the most important biological mediators and when tight interrelation of arginase and NO synthase was found, that the development of arginase inhibitors was accelerated. The regulation of arginase activity by the N-hydroxy-L-arginine (3, NOHA) intermediate of the NO synthesis was the starting point of the N-hydroxy-nor-arginine (21, nor-NOHA) that proved to be the first micromolar inhibitor. The previously known manganese and arginase binding by borate inspired the 2(S)-amino-6-boronohexanoic acid (39, ABH) and S-(2-boronoethyl)-L-cysteine (40, BEC) now both considered as reference compounds in arginase inhibition. The high-resolution crystal structure of arginase and molecular modeling has rendered possible the recent design of (53) the strongest α,α-disubstituted derivatives of ABH. Simultaneously, traditional medicinal plants have contributed as a source of molecular diversity to the discovery of arginase inhibitors. This rational, step-by-step approach serves as guide in the present review where emphasis is placed on structure activity relationships. Highlights exhaustive review on arginase inhibitors highlight is made on rational approach to conception and structure activity relationships evaluation model is systematically mentioned with results.


Subject(s)
Arginase/antagonists & inhibitors , Enzyme Inhibitors/pharmacology , Animals , Arginase/metabolism , Biocatalysis/drug effects , Biological Products/chemistry , Biological Products/pharmacology , Communicable Diseases/enzymology , Enzyme Inhibitors/chemistry , Health , Humans
15.
Cardiovasc Res ; 112(1): 429-42, 2016 10.
Article in English | MEDLINE | ID: mdl-27496869

ABSTRACT

Proprotein convertase subtilisin kexin 9 (PCSK9) is a key regulator of low-density lipoprotein receptor levels and LDL-cholesterol levels. Loss-of-function mutations in PCSK9 gene are associated with hypocholesterolaemia and protection against cardiovascular disease, identifying PCSK9 inhibition as a valid therapeutic approach to manage hypercholesterolaemia and related diseases. Although PCSK9 is expressed mainly in the liver, it is present also in other tissues and organs with specific functions, raising the question of whether a pharmacological inhibition of PCSK9 to treat hypercholesterolaemia and associated cardiovascular diseases might be helpful or deleterious in non-hepatic tissues. For example, PCSK9 is expressed in the vascular wall, in the kidneys, and in the brain, where it was proposed to play a role in development, neurocognitive process, and neuronal apoptosis. A link between PCSK9 and immunity was also proposed as both sepsis and viral infections are differentially affected in the presence or absence of PCSK9. Despite the increasing number of observations, the debate on the exact roles of PCSK9 in extrahepatic tissues is still ongoing, and as very effective drugs that inhibit PCSK9 have become available to the clinician, a better understanding of the biological roles of PCSK9 is warranted.


Subject(s)
Anticholesteremic Agents/therapeutic use , Cholesterol, LDL/blood , Hypercholesterolemia/drug therapy , PCSK9 Inhibitors , Serine Proteinase Inhibitors/therapeutic use , Adipose Tissue/drug effects , Adipose Tissue/enzymology , Adiposity/drug effects , Animals , Anticholesteremic Agents/adverse effects , Biomarkers/blood , Blood Glucose/drug effects , Blood Glucose/metabolism , Brain/drug effects , Brain/enzymology , Communicable Diseases/enzymology , Down-Regulation , Humans , Hypercholesterolemia/blood , Hypercholesterolemia/enzymology , Kidney/drug effects , Kidney/enzymology , Lipid Metabolism/drug effects , Liver/drug effects , Liver/enzymology , Proprotein Convertase 9/metabolism , Serine Proteinase Inhibitors/adverse effects
16.
BMC Ophthalmol ; 16: 19, 2016 Feb 16.
Article in English | MEDLINE | ID: mdl-26879979

ABSTRACT

BACKGROUND: Increased serum levels of angiotensin converting enzyme and lysozyme are considered as inflammatory markers for diagnosis of sarcoidosis which is an autoimmune inflammatory disease. The purpose of this study is to evaluate the significance of differences in serum angiotensin converting enzyme and lysozyme levels of patients with ocular involvement of other autoimmune inflammatory and infectious diseases. METHODS: This is a prospective study involving patients with ankylosing spondylitis, behcet's disease, presumed sarcoidosis, presumed latent tuberculosis, presumed latent syphilis, and control group. The serum levels of angiotensin converting enzyme and lysozyme were analyzed by enzyme-linked immunosorbent assay. Bonnferoni analysis was used to assess pairwise comparisons between the groups. RESULTS: There was a significant increase in serum angiotensin converting enzyme level in patients with presumed sarcoidosis compared to ankylosing spondylitis (p = 0.0001), behcet's disease (p = 0.0001), presumed latent tuberculosis (p = 0.0001), presumed latent syphilis (p = 0.0001), and control group (p = 0.0001). The increase in serum lysozyme level was significant for patients with presumed sarcoidosis with respect to ankylosing spondylitis (p = 0.0001), behcet's disease, (p = 0.0001) presumed latent tuberculosis (p = 0.001), presumed latent syphilis (p = 0.033), and control group (p = 0.0001). CONCLUSION: Elevated serum angiotensin converting enzyme levels are significant for patients with presumed sarcoidosis compared to ocular involvement of other autoimmune diseases such as behcet's disease and ankylosing spondylitis, and ocular involvement of infectious diseases such as presumed latent tuberculosis and presumed latent syphilis. However, elevated serum lysozyme level might be also detected in ocular involvement of infectious diseases such as presumed latent tuberculosis and presumed latent syphilis. TRIAL REGISTRATION NUMBER: NCT02627209. Date of registration: 12/09/2015.


Subject(s)
Behcet Syndrome/enzymology , Latent Tuberculosis/enzymology , Muramidase/blood , Peptidyl-Dipeptidase A/blood , Sarcoidosis/enzymology , Spondylitis, Ankylosing/enzymology , Syphilis/enzymology , Adolescent , Adult , Aged , Aged, 80 and over , Autoimmune Diseases/enzymology , Child , Communicable Diseases/enzymology , Enzyme-Linked Immunosorbent Assay , Female , Humans , Male , Middle Aged , Prospective Studies
17.
Curr Drug Targets ; 17(8): 942-53, 2016.
Article in English | MEDLINE | ID: mdl-25882224

ABSTRACT

Intracellular pathogens are known to manipulate host cell regulatory pathways to establish an optimal environment for their growth and survival. Pathogens employ active mechanisms to hijack host cell metabolism and acquire existing nutrient and energy store. The role of the cellular energy sensor AMP-activated protein kinase (AMPK) in the regulation of cellular energy homeostasis is well documented. Here, we highlight recent advances showing the importance of AMPK signaling in pathogen-host interactions. Pathogens interact with AMPK by a variety of mechanisms aimed at reprogramming host cell metabolism to their own benefit. Stimulation of AMPK activity provides an efficient process to rapidly adapt pathogen metabolism to the major nutritional changes often encountered during the different phases of infection. However, inhibition of AMPK is also used by pathogens to manipulate innate host response, indicating that AMPK appears relevant to restriction of pathogen infection. We also document the effects of pharmacological AMPK modulators on pathogen proliferation and survival. This review illustrates intricate pathogen-AMPK interactions that may be exploited to the development of novel anti-pathogen therapies.


Subject(s)
AMP-Activated Protein Kinases/metabolism , Bacterial Physiological Phenomena , Communicable Diseases/enzymology , Parasites/physiology , Virus Physiological Phenomena , AMP-Activated Protein Kinases/antagonists & inhibitors , AMP-Activated Protein Kinases/chemistry , Animals , Anti-Infective Agents/pharmacology , Bacterial Physiological Phenomena/drug effects , Communicable Diseases/microbiology , Communicable Diseases/parasitology , Energy Metabolism , Enzyme Activation , Homeostasis , Host-Pathogen Interactions , Humans , Immunity, Innate , Parasites/drug effects , Phosphorylation , Protein Interaction Maps , Signal Transduction , Virus Physiological Phenomena/drug effects
18.
Crit Rev Microbiol ; 40(4): 360-8, 2014 Nov.
Article in English | MEDLINE | ID: mdl-23174025

ABSTRACT

Indoleamine-2,3-dioxygenase (IDO) is an enzyme that catabolises tryptophan - an essential amino acid critical for T cell proliferation. Initially recognized as a first line of host defense against infectious pathogens, IDO has been subsequently identified as an important immune-regulator inhibiting T-cell responses and promoting immune tolerance. Research over the past few years has demonstrated a crucial role for IDO in the pathogenesis of persistent infections that place an enormous burden on public health. In this review, we summarize current knowledge about IDO's role in causing pathogen persistence and progression to clinical disease. We conclude with a perspective on the potential benefits and risks of therapeutic IDO manipulation.


Subject(s)
Communicable Diseases/enzymology , Communicable Diseases/therapy , Indoleamine-Pyrrole 2,3,-Dioxygenase/metabolism , Animals , Chronic Disease , Communicable Diseases/etiology , Humans , Immunomodulation , Immunotherapy , Metabolic Networks and Pathways , Tryptophan/metabolism
19.
Top Curr Chem ; 344: 293-329, 2014.
Article in English | MEDLINE | ID: mdl-23666077

ABSTRACT

Aminoacyl-tRNA synthetases (AARSs) play a pivotal role in protein synthesis and cell viability. These 22 "housekeeping" enzymes (1 for each standard amino acid plus pyrrolysine and o-phosphoserine) are specifically involved in recognizing and aminoacylating their cognate tRNAs in the cellular pool with the correct amino acid prior to delivery of the charged tRNA to the protein synthesis machinery. Besides serving this canonical function, higher eukaryotic AARSs, some of which are organized in the cytoplasm as a multisynthetase complex of nine enzymes plus additional cellular factors, have also been implicated in a variety of non-canonical roles. AARSs are involved in the regulation of transcription, translation, and various signaling pathways, thereby ensuring cell survival. Based in part on their versatility, AARSs have been recruited by viruses to perform essential functions. For example, host synthetases are packaged into some retroviruses and are required for their replication. Other viruses mimic tRNA-like structures in their genomes, and these motifs are aminoacylated by the host synthetase as part of the viral replication cycle. More recently, it has been shown that certain large DNA viruses infecting animals and other diverse unicellular eukaryotes encode tRNAs, AARSs, and additional components of the protein-synthesis machinery. This chapter will review our current understanding of the role of host AARSs and tRNA-like structures in viruses and discuss their potential as anti-viral drug targets. The identification and development of compounds that target bacterial AARSs, thereby serving as novel antibiotics, will also be discussed. Particular attention will be given to recent work on a number of tRNA-dependent AARS inhibitors and to advances in a new class of natural "pro-drug" antibiotics called Trojan Horse inhibitors. Finally, we will explore how bacteria that naturally produce AARS-targeting antibiotics must protect themselves against cell suicide using naturally antibiotic resistant AARSs, and how horizontal gene transfer of these AARS genes to pathogens may threaten the future use of this class of antibiotics.


Subject(s)
Amino Acyl-tRNA Synthetases/metabolism , Communicable Diseases/drug therapy , Communicable Diseases/enzymology , Drug Discovery/methods , Molecular Targeted Therapy/methods , Amino Acyl-tRNA Synthetases/antagonists & inhibitors , Amino Acyl-tRNA Synthetases/chemistry , Amino Acyl-tRNA Synthetases/genetics , Bacterial Infections/drug therapy , Bacterial Infections/enzymology , Base Sequence , Humans , Virus Diseases/drug therapy , Virus Diseases/enzymology
20.
Pharm Pat Anal ; 3(1): 65-85, 2014 Jan.
Article in English | MEDLINE | ID: mdl-24354980

ABSTRACT

Arginase is an enzyme that metabolizes L-arginine to L-ornithine and urea. In addition to its fundamental role in the hepatic ornithine cycle, it also influences the immune systems in humans and mice. Arginase participates in many inflammatory disorders by decreasing the synthesis of nitric oxide and inducing fibrosis and tissue regeneration. L-arginine deficiency, which is modulated by myeloid cell arginase, suppresses T-cell immune response. This mechanism plays a fundamental role in inflammation-associated immunosuppression. Pathogens can synthesize their own arginase to elude immune reaction. Small-molecule arginase inhibitors are currently described as promising therapeutics for the treatment of several diseases, including allergic asthma, inflammatory bowel disease, ulcerative colitis, cardiovascular diseases (atherosclerosis and hypertension), diseases associated with pathogens (e.g., Helicobacter pylori, Trypanosoma cruzi, Leishmania, Mycobacterium tuberculosis and Salmonella), cancer and induced or spontaneous immune disorders. This article summarizes recent patents in the area of arginase inhibitors and discusses their properties.


Subject(s)
Arginase/antagonists & inhibitors , Enzyme Inhibitors/chemistry , Enzyme Inhibitors/therapeutic use , Patents as Topic , Animals , Arginase/chemistry , Arginase/metabolism , Cardiovascular Diseases/drug therapy , Cardiovascular Diseases/enzymology , Communicable Diseases/drug therapy , Communicable Diseases/enzymology , Crystallography, X-Ray , Enzyme Inhibitors/metabolism , Humans , Patents as Topic/legislation & jurisprudence
SELECTION OF CITATIONS
SEARCH DETAIL
...